NCT03361228 - A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat, With or Without Pembrolizumab, in Advanced Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 1, 2018

Primary Completion Date

March 30, 2019

Study Completion Date

March 30, 2019

Conditions

Solid Tumors

Interventions

DRUG

INCB001158

Phase 1: INCB001158 administered orally twice daily at the protocol-defined dose. Phase 2: INCB001158 administered orally twice daily at the recommended dose from Phase 1.

DRUG

Epacadostat

Epacadostat at the protocol-defined dose administered orally twice daily.

DRUG

Pembrolizumab

Pembrolizumab at the protocol-defined dose administered intravenously every 3 weeks.

Trial Locations (2)

60637

The University of Chicago Medicine, Chicago

35294-3300

University of Alabama, Birmingham